国际肿瘤学杂志 ›› 2022, Vol. 49 ›› Issue (11): 641-657.doi: 10.3760/cma.j.cn371439-20221011-00129
• 指南·共识 • 下一篇
中国医师协会放射肿瘤治疗医师分会,中华医学会放射肿瘤治疗学分会,中国抗癌协会肿瘤放射治疗专业委员会
收稿日期:2022-10-11
修回日期:2022-10-16
出版日期:2022-11-08
发布日期:2022-12-06
Received:2022-10-11
Revised:2022-10-16
Online:2022-11-08
Published:2022-12-06
中国医师协会放射肿瘤治疗医师分会,中华医学会放射肿瘤治疗学分会,中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2022年版）[J]. 国际肿瘤学杂志, 2022, 49(11): 641-657.
图1
pTis-T1aN0期食管癌治疗策略注：ESD为内镜下黏膜下剥离术；EMR为内镜下黏膜切除术；MBM为多环黏膜切除术；SM1为黏膜下层上1/3"
图2
cT1b-2N0期食管癌治疗策略"
图3
cT1b-2N+或cT3-4aN0/N+期食管癌治疗策略"
图4
cT4bN0/N+期食管癌治疗策略"
图5
远处转移食管癌治疗策略"
图6
未行新辅助治疗食管癌R0术后治疗策略注：a高危pT2N0指存在低分化、脉管癌栓、神经侵犯、<50岁中的任一项"
图7
食管癌R1/R2切除者治疗策略"
图8
食管癌放疗后局部复发转移者治疗策略"
图9
食管癌患者放疗适应证"
图10
食管癌患者放疗禁忌证或相对禁忌证"
图11
颈段食管癌适形计划射野分布及BEV所示肿瘤与脊髓的相对位置 A为颈段食管癌4野共面适形照射示意图；B~E为4个照射野在BEV可见肿瘤和脊髓的相对位置，以及多叶光栅、准直器设置注：BEV为射野方向观"
图12
胸段食管癌适形计划射野分布及BEV所示肿瘤与脊髓的相对位置 A为中下段食管癌5野共面适形照射示意图；B~F为5个照射野在BEV可见肿瘤和脊髓的相对位置，以及多叶光栅、准直器设置注：BEV为射野方向观"
表1
食管癌放疗危及器官受量推荐"
| 器官 | 剂量约束条件 | 对应并发症风险 |
|---|---|---|
| 脊髓 | 颈段≤45 Gy，胸段脊髓≤50 Gy | 放射性脊髓病变 |
| 双肺 | V5<63%，V20≤30% | 有症状的放射性肺炎风险<20% |
| Dmean=7 Gy、13 Gy、20 Gy、24 Gy、27 Gy | 有症状的放射性肺炎风险分别为5%、10%、20%、30%、40% | |
| 心脏 | Dmean<26 Gy | 心包炎风险<15% |
| V30<46% | 心包炎风险<15% | |
| V25<10% | 远期心源性死亡风险<1% | |
| 肝脏 | Dmean<30~32 Gy | 典型放射性肝病风险<5%（适用于不存在既往肝病或肝细胞癌的患者） |
| Dmean<28 Gy | 典型放射性肝病风险<5%（适用于既往有肝脏疾病或肝细胞癌的肝功能Child-Pugh A级患者，且排除乙型肝炎病毒再激活患者） | |
| 气管 | 文献罕见关于常规分割下气管耐受剂量的报道，建议气管可耐受的最大剂量<75 Gy，并避免热点剂量（≥110%处方剂量）落入靶区内气管壁 | |
| 胃 | 受照体积为1/3、2/3、全胃的TD5/5分别为60 Gy、55 Gy和50 Gy，TD50/5分别为70 Gy、67 Gy和65 Gy | |
| 建议接受40 Gy的胃体积应小于全部胸腔胃的40%~50% | ||
| D100%<45 Gy | 胃溃疡风险<7% |
表2
食管癌特殊放疗技术的剂量推荐"
| 放疗技术 | 推荐剂量 | 危及器官受量 |
|---|---|---|
| 质子放疗 | 肺平均剂量<20 Gy（RBE），全肺V20<30%，心脏V40<40%，肝脏V30<30%，脊髓最大剂量<45 Gy（RBE） | |
| 新辅助治疗 | 40~50.4 Gy（RBE），常规分割 | |
| 鳞癌根治性同步放化疗 | 50.4~60 Gy（RBE），常规分割（化疗方案为氟尿嘧啶+顺铂） | |
| 腺癌根治性同步放化疗 | 中位剂量50.4 Gy（RBE）[36~63 Gy（RBE）]，常规分割（化疗方案为 氟尿嘧啶+顺铂） | |
| 单纯质子治疗 | 中位剂量50~65 Gy（RBE） | |
| 辅助放疗 | 45~50.4 Gy（RBE），常规分割 | |
| 与X线联合照射 | X线中位剂量36 Gy（16.2~60 Gy，常规分割），质子中位剂量36 Gy （RBE）[17.5~54.5 Gy，2.5~3.7 Gy（RBE）/次]，常规分割 | |
| 放化疗后复发者 | 中位剂量54.0 Gy（RBE）[50.4~61.2 Gy（RBE）]，常规分割 | |
| 碳离子放疗 | 食管Dmax<60 Gy（RBE） Dmax<40 Gy（RBE）[5 Gy（RBE）/次] | |
| Ⅱ、Ⅲ期新辅助放疗 | 33.6 Gy（RBE）/8次 | |
| Ⅰ期根治性放疗 | 48~50.4 Gy（RBE）/12次 | |
| 根治术后孤立复发淋巴结 | 48 Gy（RBE）/12次 | |
| 后装腔内放疗 | 暂缺 | |
| 放疗未控不宜手术者 | 后装补量10~20 Gy | |
| 原发灶放化疗后复发 | 外照射40~50 Gy，后装3~5 Gy/次，2~3次；或单纯后装20~40 Gy | |
| 放射性粒子植入 | 暂缺 | |
| 放疗后6个月内复发 | 100~120 Gy | |
| 放疗后6个月以上复发 | 120~160 Gy |
表3
食管癌新辅助放化疗方案"
| 方案 | 剂量及用法 | 推荐等级 |
|---|---|---|
| 首选方案 | ||
| 紫杉醇+卡铂 | 紫杉醇50 mg/m2 d1，卡铂AUC=2 d1，qw，共5周 | Ⅰ级推荐，1A类证据 |
| 顺铂+氟尿嘧啶/卡培他滨/替吉奥 | 顺铂75~100 mg/m2 d1、29，氟尿嘧啶750~1 000 mg/m2 qd CIV d1~4、d29~32，q5w；或顺铂15 mg/m2 d1~5，氟尿嘧啶800 mg/m2 qd CIV 120 h，q3w，共2周期 | Ⅰ级推荐，1A类证据 |
| 顺铂30 mg/m2 d1，卡培他滨800 mg/m2 bid d1~5，qw，共5周 | ||
| 顺铂70 mg/m2 d1，替吉奥40 mg/m2 bid（最大日剂量100 mg） d1~14，q3w，共2周期 | ||
| 长春瑞滨+顺铂 | 长春瑞滨25 mg/m2 d1、8，顺铂75 mg/m2 d1或25 mg/m2 d1~4，q3w，共2周期 | Ⅰ级推荐，1A类证据 |
| 奥沙利铂+氟尿嘧啶/卡培他滨/ 替吉奥（腺癌） | 奥沙利铂85 mg/m2 d1，亚叶酸钙400 mg/m2d1，氟尿嘧啶400 mg/m2 IV d1， 2 400 mg/m2 CIV 46 h，q2w，共3周期 | Ⅰ级推荐，2B类证据 |
| 奥沙利铂85 mg/m2 d1、15、29，卡培他滨625 mg/m2 bid d1~5，qw，共5周 | ||
| 奥沙利铂100 mg/m2 d1，替吉奥40~60 mg bid d1~14，q3w，共2周期 | ||
| 其他方案 | ||
| 多西他赛+顺铂/卡铂 | 多西他赛75 mg/m2 d1，顺铂75 mg/m2 d1，q3w，共2周期 | Ⅰ级推荐，2A类证据 |
| 多西他赛75 mg/m2 d1，卡铂AUC=5~6 d1，q3w，共2周期 | ||
| 紫杉醇+氟尿嘧啶/卡培他滨 | 紫杉醇45~50 mg/m2 d1，氟尿嘧啶300 mg/m2 CIV d1~5，qw，连用5周 | Ⅰ级推荐，2B类证据 |
| 紫杉醇45~50 mg/m2 d1，卡培他滨625~825 mg/m2 bid d1~5，qw，连用5周 |
表4
食管癌新辅助化疗方案"
| 方案 | 剂量及用法 | 推荐等级 |
|---|---|---|
| 顺铂+氟尿嘧啶 | 顺铂80 mg/m2 d1，氟尿嘧啶1 000 mg/m2 d1~4，q3w，共2周期 | Ⅰ级推荐，1A类证据 |
| 紫杉醇+顺铂（鳞癌） | 紫杉醇150 mg/m2 d1，顺铂50 mg/m2 d1，q2w，共3周期 | Ⅰ级推荐，1A类证据 |
| 奥沙利铂+氟尿嘧啶类（腺癌） | 奥沙利铂85 mg/m2 d1，氟尿嘧啶400 mg/m2 IV d1，2 400 mg/m2 CIV 46 h，q2w， 共3周期 | Ⅰ级推荐，1A类证据 |
| 奥沙利铂130 mg/m2 d1，卡培他滨1 000 mg/m2 bid d1~14，q3w | Ⅰ级推荐，1A类证据 | |
| 多西他赛+奥沙利铂+亚叶酸钙+ 氟尿嘧啶（FLOT，腺癌） | 多西他赛50 mg/m2 d1，奥沙利铂85 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶2 600 mg/m2 CIV d1，q2w，术前4个周期+术后4个周期，共8周期 | Ⅰ级推荐，1A类证据 |
表5
食管癌根治性放化疗方案"
| 方案 | 剂量及用法 | 推荐等级 |
|---|---|---|
| 首选方案 | ||
| 顺铂+氟尿嘧啶 | 顺铂75~100 mg/m2 d1，氟尿嘧啶750~1 000 mg/m2 CIV 96 h，q4w，同步放疗2周期，放疗后2周期 | Ⅰ级推荐，1A类证据 |
| 顺铂+卡培他滨 | 卡培他滨800 mg/m2 bid d1~5，顺铂30 mg/m2 d1，qw，共5周 | Ⅰ级推荐，1A类证据 |
| 紫杉醇+卡铂 | 紫杉醇50 mg/m2 d1，卡铂AUC=2 d1，qw，共5周 | Ⅰ级推荐，1A类证据 |
| 奥沙利铂+氟尿嘧（腺癌） | 奥沙利铂85 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶400 mg/m2 IV d1，2 400 mg/m2 CIV 46 h，q2w，同步放疗3周期，放疗后3周期 | Ⅰ级推荐，1A类证据 |
| 奥沙利铂+卡培他滨（腺癌） | 奥沙利铂85 mg/m2 d1、15、29，卡培他滨625 mg/m2 bid d1~5，qw，共3次，共5周 | Ⅰ级推荐，2B类证据 |
| 紫杉醇+氟尿嘧啶 | 紫杉醇50 mg/m2 d1，氟尿嘧啶300 mg/m2 CIV 96 h，qw，共5周。放疗结束后巩固2周期：紫杉醇175 mg/m2 d1，氟尿嘧啶1 800 mg/m2 CIV 72 h，q4w | Ⅰ级推荐，2B类证据 |
| 其他方案 | ||
| 多西他赛或紫杉醇+顺铂 | 多西他赛20~30 mg/m2 d1，顺铂20~30 mg/m2 d1，qw，连用5周；或多西他赛60 mg/m2 d1，顺铂60~80 mg/m2 d1，q3w，共2周期 | Ⅰ级推荐，2A类证据 |
| 紫杉醇45~50 mg/m2 d1，顺铂20 mg/m2 d1，qw，共6周期 | ||
| 顺铂+伊立替康 | 顺铂20 mg/m2 d1，伊立替康60 mg/m2 d1，qw，共6周期 | Ⅰ级推荐，2A类证据 |
| 紫杉醇+卡培他滨 | 紫杉醇45~50 mg/m2 d1，卡培他滨625~825 mg/m2 bid，d1~5，qw，连用5周 | Ⅰ级推荐，2B类证据 |
| 替吉奥单药（≥70岁者） | 替吉奥40 mg/m2 bid d1~14，q3w，同步放疗2周期，放疗后2周期 | Ⅰ级推荐，1A类证据 |
表6
食管癌术后化疗/放化疗方案"
| 方案 | 剂量及用法 | 推荐级别 |
|---|---|---|
| 顺铂+氟尿嘧啶类 | 顺铂50 mg/m2 d1，q2w，氟尿嘧啶1 000 mg/m2 CIV d1~2，术前4~6周期+术后4~6周期，共12周期 | Ⅰ级推荐，1A类证据 |
| 顺铂80 mg/m2 d1，卡培他滨1 000 mg/m2 bid d1~14，q3w，共6周期 | ||
| 顺铂80 mg/m2 d1，替吉奥40~60 mg bid d1~14，q3w，共6周期 | ||
| 紫杉醇+卡铂 | 紫杉醇135~175 mg/m2 d1，卡铂AUC=5~6 d1，q3w，共6周期 | Ⅰ级推荐，1A类证据 |
| 紫杉醇+顺铂（鳞癌） | 紫杉醇150 mg/m2 d1，顺铂50 mg/m2 d1，q2w，共6周期 | Ⅰ级推荐，2A类证据 |
| 奥沙利铂+氟尿嘧啶类（腺癌） | 奥沙利铂85 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶400 mg/m2 IV d1，2 400 mg/m2 CIV 46 h，q2w；或奥沙利铂85 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶2 600 mg/m2 CIV 46 h，q2w，共12周期 | Ⅰ级推荐，1A类证据 |
| 奥沙利铂130 mg/m2 d1，q3w，卡培他滨1 000 mg/m2 bid d1~14，共8周期 | ||
| 奥沙利铂130 mg/m2 d1，替吉奥40~60 mg bid d1~14，q3w，共8周期 |
表7
食管癌姑息性化疗方案"
| 方案 | 剂量及用法 | 推荐级别 |
|---|---|---|
| 一线方案 | ||
| 顺铂+氟尿嘧啶/卡培他滨/替吉奥 | 顺铂75 mg/m2 d1，亚叶酸钙200 mg/m2 d1，氟尿嘧啶750~1 000 mg/m2 CIV d1~4，q3w；或顺铂50 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶400 mg IV， 2 400 mg/m2 CIV 46 h，q2w | 腺癌Ⅰ级推荐，1A类证据； 鳞癌Ⅰ级推荐，2A类证据 |
| 顺铂80 mg/m2 d1，卡培他滨1 000 mg/m2 bid d1~14，q3w | ||
| 顺铂80 mg/m2 d1，替吉奥40~60 mg bid d1~14，q3w | ||
| 奥沙利铂+氟尿嘧啶类（腺癌） | 奥沙利铂85 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶400 mg/m2 IV d1， 2 400 mg/m2 CIV 46 h，q2w；或奥沙利铂85 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶2 400 mg/m2 CIV 46 h，q2w | Ⅰ级推荐，2A类证据 |
| 奥沙利铂130 mg/m2 d1，卡培他滨1 000 mg/m2 bid d1~14，q3w | ||
| 多西他赛+顺铂+氟尿嘧啶（腺癌） | 多西他赛40 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶400 mg/m2 IV d1， 2 400 mg/m2 CIV 46 h，顺铂40 mg/m2 d3，q2w | Ⅰ级推荐，1A类证据 |
| 多西他赛+奥沙利铂+氟尿嘧啶 （腺癌） | 多西他赛50 mg/m2 d1，奥沙利铂85 mg/m2 d1，氟尿嘧啶2 400 mg/m2 CIV 46 h， q2w | Ⅰ级推荐，1A类证据 |
| 紫杉醇/多西他赛+顺铂/奈达铂 | 紫杉醇175 mg/m2 d1，顺铂75 mg/m2 d1，q3w | Ⅱ级推荐，2A类证据 |
| 紫杉醇175 mg/m2 d1，奈达铂80~100 mg/m2 d1，q3w | ||
| 多西他赛70~85 mg/m2 d1，顺铂70~75 mg/m2 d1，q3w | ||
| 多西他赛70~85 mg/m2 d1，奈达铂80~100 mg/m2 d1，q3w | ||
| 长春瑞滨+顺铂/奈达铂 | 长春瑞滨25 mg/m2 d1、8，顺铂80 mg/m2 d1，q3w | Ⅱ级推荐，2A类证据 |
| 长春瑞滨25 mg/m2 d1、8，奈达铂80~100 mg/m2 d1，q3w | ||
| 伊立替康+氟尿嘧啶/卡培他滨/ 替吉奥 | 伊立替康180 mg/m2 d1，亚叶酸钙400 mg/m2 d1，氟尿嘧啶400 mg/m2 IV d1， 2 400 mg/m2 CIV 46 h，q2w；或伊立替康80 mg/m2 d1，亚叶酸钙500 mg/m2 d1， 氟尿嘧啶1 200 mg/m2 CIV d1，qw，连续6周后停2周（仅限于腺癌） | Ⅱ级推荐，2A类证据 |
| 卡培他滨800 mg/m2 bid d1~14，伊立替康200 mg/m2 d1，q3w | ||
| 伊立替康160 mg/m2 d1，替吉奥40~60 mg bid d1~10，q2w | ||
| 白蛋白结合型紫杉醇+顺铂（鳞癌） | 白蛋白结合型紫杉醇125 mg/m2 d1、d8，顺铂75 mg/m2 d1，q3w | Ⅲ级推荐，3类证据 |
| 二线及以后方案 | ||
| 紫杉类单药 | 紫杉醇175 mg/m2 d1，q3w，或80 mg/m2 d1、8、15、22，q4w，或80 mg/m2 d1、8、 15，q4w | 腺癌Ⅰ级推荐，1A类证据； 鳞癌Ⅱ级推荐，3类证据 |
| 多西他赛75~100 mg/m2 d1，q3w | ||
| 脂质体紫杉醇175 mg/m2 d1，q3w | ||
| 白蛋白结合型紫杉醇100~150 mg/m2 d1、8，q3w | ||
| 伊立替康单药 | 伊立替康150~180 mg/m2 d1，q2w，或125 mg/m2 d1、8，q3w | 腺癌Ⅰ级推荐，1A类证据； 鳞癌Ⅱ级推荐，3类证据 |
| [1] | NCCN Guidelines of Esophageal and Esophagogastric Junction Cancers, Version 2. 2021[EB/OL]. [2021-06-22]. https://www.nccn.org/. |
| [2] |
Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9. DOI: 10.1016/j.jncc.2022.02.002.
doi: 10.1016/j.jncc.2022.02.002 |
| [3] | 中国抗癌协会食管癌专业委员会. 食管癌规范化诊治指南[M]. 北京: 中国协和医科大学出版社, 2011. |
| [4] |
Gibault L, Metges JP, Conan-Charlet V, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer[J]. Br J Cancer, 2005, 93(1): 107-115. DOI: 10.1038/sj.bjc.6602625.
doi: 10.1038/sj.bjc.6602625 |
| [5] |
Tsutsumi S, Saeki H, Nakashima Y, et al. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma[J]. Cancer Sci, 2017, 108(6): 1119-1127. DOI: 10.1111/cas.13237.
doi: 10.1111/cas.13237 |
| [6] |
Bunting D, Bracey T, Fox B, et al. Loco-regional staging accuracy in oesophageal cancer—How good are we in the modern era?[J]. Eur J Radiol, 2017, 97: 71-75. DOI: 10.1016/j.ejrad.2017.10.015.
doi: S0720-048X(17)30409-6 pmid: 29153370 |
| [7] |
el-Khoury GY, Dalinka MK, Alazraki N, et al. Metastatic bone disease. American College of Radiology. ACR Appropriateness Criteria[J]. Radiology, 2000, 215 Suppl: 283-293.
pmid: 11037439 |
| [8] |
Minashi K, Nihei K, Mizusawa J, et al. Efficacy of endoscopic resection and selective chemoradiotherapy for stage Ⅰ esophageal squamous cell carcinoma[J]. Gastroenterology, 2019, 157(2): 382-390.e3. DOI: 10.1053/j.gastro.2019.04.017.
doi: S0016-5085(19)36710-1 pmid: 31014996 |
| [9] |
Kato H, Sato A, Fukuda H, et al. A phase Ⅱ trial of chemoradiotherapy for stage Ⅰ esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708)[J]. Jpn J Clin Oncol, 2009, 39(10): 638-643. DOI: 10.1093/jjco/hyp069.
doi: 10.1093/jjco/hyp069 |
| [10] |
Juloori A, Tucker SL, Komaki R, et al. Influence of preoperative radiation field on postoperative leak rates in esophageal cancer patients after trimodality therapy[J]. J Thorac Oncol, 2014, 9(4): 534-540. DOI: 10.1097/JTO.0000000000000100.
doi: 10.1097/JTO.0000000000000100 pmid: 24736077 |
| [11] |
Huang W, Huang Y, Sun J, et al. Atlas of the thoracic lymph nodal delineation and recommendations for lymph nodal CTV of esophageal squamous cell cancer in radiation therapy from China[J]. Radiother Oncol, 2015, 116(1): 100-106. DOI: 10.1016/j.radonc.2015.06.024.
doi: 10.1016/j.radonc.2015.06.024 pmid: 26142269 |
| [12] |
Huang W, Li B, Gong H, et al. Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume in patients with thoracic esophageal squamous cell carcinoma: a report of 1077 cases[J]. Radiother Oncol, 2010, 95(2): 229-233. DOI: 10.1016/j.radonc.2010.01.006.
doi: 10.1016/j.radonc.2010.01.006 pmid: 20189259 |
| [13] |
Cheng J, Kong L, Huang W, et al. Explore the radiotherapeutic clinical target volume delineation for thoracic esophageal squamous cell carcinoma from the pattern of lymphatic metastases[J]. J Thorac Oncol, 2013, 8(3): 359-365. DOI: 10.1097/JTO.0b013e31827e1f6d.
doi: 10.1097/JTO.0b013e31827e1f6d pmid: 23263689 |
| [14] |
Ding X, Zhang J, Li B, et al. A meta-analysis of lymph node metastasis rate for patients with thoracic oesophageal cancer and its implication in delineation of clinical target volume for radiation therapy[J]. Br J Radiol, 2012, 85(1019): e1110-e1119. DOI: 10.1259/bjr/12500248.
doi: 10.1259/bjr/12500248 |
| [15] |
Dong Y, Guan H, Huang W, et al. Precise delineation of clinical target volume for crossing-segments thoracic esophageal squamous cell carcinoma based on the pattern of lymph node metastases[J]. J Thorac Dis, 2015, 7(12): 2313-2320. DOI: 10.3978/j.issn.2072-1439.2015.12.10.
doi: 10.3978/j.issn.2072-1439.2015.12.10 pmid: 26793353 |
| [16] |
Li J, Chen S, Zhu G. Comparative study of computed tomography (CT) and pathological diagnosis toward mediastinal lymph node metastasis in esophageal carcinoma[J]. Rev Assoc Med Bras (1992), 2018, 64(2): 170-174. DOI: 10.1590/1806-9282.64.02.170.
doi: 10.1590/1806-9282.64.02.170 |
| [17] |
Huang L, Chen C, Lin M, et al. Understanding the pattern of lymph node metastasis for trans-segmental thoracic esophageal cancer to develop precise delineation of clinical target volume for radiotherapy[J]. Ann Palliat Med, 2020, 9(3): 788-794. DOI: 10.21037/apm.2020.04.10.
doi: 10.21037/apm.2020.04.10 pmid: 32389008 |
| [18] |
Shapiro J, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015, 16(9): 1090-1098. DOI: 10.1016/S1470-2045(15)00040-6.
doi: 10.1016/S1470-2045(15)00040-6 |
| [19] |
van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012, 366(22): 2074-2084. DOI: 10.1056/NEJMoa1112088.
doi: 10.1056/NEJMoa1112088 |
| [20] |
王玉祥, 杨琼, 何明, 等. Ⅲ期胸段食管鳞癌根治术后的复发规律[J]. 中华肿瘤杂志, 2017, 39(1): 48-55. DOI: 10.3760/cma.j.issn.0253-3766.2017.01.010.
doi: 10.3760/cma.j.issn.0253-3766.2017.01.010 |
| [21] |
Chapet O, Kong FM, Quint LE, et al. CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan[J]. Int J Radiat Oncol Biol Phys, 2005, 63(1): 170-178. DOI: 10.1016/j.ijrobp.2004.12.060.
doi: 10.1016/j.ijrobp.2004.12.060 |
| [22] |
Liu Q, Cai XW, Wu B, et al. Patterns of failure after radical surgery among patients with thoracic esophageal squamous cell carcinoma: implications for the clinical target volume design of post-operative radiotherapy[J]. PLoS One, 2014, 9(5): e97225. DOI: 10.1371/journal.pone.0097225.
doi: 10.1371/journal.pone.0097225 |
| [23] |
Wong AT, Shao M, Rineer J, et al. The impact of adjuvant post-operative radiation therapy and chemotherapy on survival after esophagectomy for esophageal carcinoma[J]. Ann Surg, 2017, 265(6): 1146-1151. DOI: 10.1097/SLA.0000000000001825.
doi: 10.1097/SLA.0000000000001825 |
| [24] |
Xiao ZF, Yang ZY, Liang J, et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients[J]. Ann Thorac Surg, 2003, 75(2): 331-336. DOI: 10.1016/s0003-4975(02)04401-6.
doi: 10.1016/s0003-4975(02)04401-6 pmid: 12607634 |
| [25] |
Worni M, Martin J, Gloor B, et al. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008[J]. J Am Coll Surg, 2012, 215(5): 643-651. DOI: 10.1016/j.jamcollsurg.2012.07.006.
doi: 10.1016/j.jamcollsurg.2012.07.006 |
| [26] |
Chen J, Zhu J, Pan J, et al. Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus[J]. Ann Thorac Surg, 2010, 90(2): 435-442. DOI: 10.1016/j.athoracsur.2010.04.002.
doi: 10.1016/j.athoracsur.2010.04.002 pmid: 20667325 |
| [27] |
Ni W, Yu S, Xiao Z, et al. Postoperative adjuvant therapy versus surgery alone for stage ⅡB-Ⅲ esophageal squamous cell carcinoma: a phase Ⅲ randomized controlled trial[J]. Oncologist, 2021, 26(12): e2151-e2160. DOI: 10.1002/onco.13914.
doi: 10.1002/onco.13914 |
| [28] |
Schreiber D, Rineer J, Vongtama D, et al. Impact of postoperative radiation after esophagectomy for esophageal cancer[J]. J Thorac Oncol, 2010, 5(2): 244-250. DOI: 10.1097/JTO.0b013e3181c5e34f.
doi: 10.1097/JTO.0b013e3181c5e34f pmid: 20009774 |
| [29] |
Shridhar R, Weber J, Hoffe SE, et al. Adjuvant radiation therapy and lymphadenectomy in esophageal cancer: a SEER database analysis[J]. J Gastrointest Surg, 2013, 17(8): 1339-1345. DOI: 10.1007/s11605-013-2192-7.
doi: 10.1007/s11605-013-2192-7 pmid: 23749498 |
| [30] |
Xu Y, Liu J, Du X, et al. Prognostic impact of postoperative radiation in patients undergoing radical esophagectomy for pathologic lymph node positive esophageal cancer[J]. Radiat Oncol, 2013, 8: 116. DOI: 10.1186/1748-717X-8-116.
doi: 10.1186/1748-717X-8-116 pmid: 23656920 |
| [31] |
Zhang W, Liu X, Xiao Z, et al. Postoperative intensity-modulated radiotherapy improved survival in lymph node-positive or stage Ⅲ thoracic esophageal squamous cell carcinoma[J]. Oncol Res Treat, 2015, 38(3): 97-102. DOI: 10.1159/000375391.
doi: 10.1159/000375391 |
| [32] |
Chen SB, Weng HR, Wang G, et al. The impact of adjuvant radiotherapy on radically resected T3 esophageal squamous cell carcinoma[J]. J Cancer Res Clin Oncol, 2016, 142(1): 277-286. DOI: 10.1007/s00432-015-2041-z.
doi: 10.1007/s00432-015-2041-z |
| [33] |
刘晓, 章文成, 于舒飞, 等. T2-3N0M0期食管癌R0术后失败模式分析——术后放疗潜在价值与意义[J]. 中华放射肿瘤学杂志, 2015, 24(1): 19-24. DOI: 10.3760/cma.j.issn.1004-4221.2015.01.006.
doi: 10.3760/cma.j.issn.1004-4221.2015.01.006 |
| [34] |
Deng W, Yang J, Ni W, et al. Postoperative radiotherapy in pathological T2-3N0M0 thoracic esophageal squamous cell carcinoma: interim report of a prospective, phase Ⅲ, randomized controlled study[J]. Oncologist, 2020, 25(4): e701-e708. DOI: 10.1634/theoncologist.2019-0276.
doi: 10.1634/theoncologist.2019-0276 |
| [35] |
Yang J, Zhang W, Xiao Z, et al. The impact of postoperative conformal radiotherapy after radical surgery on survival and recurrence in pathologic T3N0M0 esophageal carcinoma: a propensity score-matched analysis[J]. J Thorac Oncol, 2017, 12(7): 1143-1151. DOI: 10.1016/j.jtho.2017.03.024.
doi: 10.1016/j.jtho.2017.03.024 |
| [36] |
祝淑钗, 李巧芳, 张雪原, 等. 食管癌根治性调强放疗靶区范围对患者预后的影响[J]. 中华肿瘤杂志, 2020, 42(12): 1040-1047. DOI: 10.3760/cma.j.cn112152-20191225-00842.
doi: 10.3760/cma.j.cn112152-20191225-00842 |
| [37] |
祝淑钗, 董辉, 沈文斌, 等. 食管癌调强放疗淋巴引流区预防照射的同期对照研究[J]. 中华放射医学与防护杂志, 2014, 34(10): 758-762. DOI: 10.3760/cma.j.issn.0254-5098.2014.10.009.
doi: 10.3760/cma.j.issn.0254-5098.2014.10.009 |
| [38] |
祝淑钗, 董辉, 刘志坤, 等. 早期食管癌根治性放射治疗不同照射范围的比较研究[J]. 中华放射肿瘤学杂志, 2015, 24(6): 615-618. DOI: 10.3760/cma.j.issn.1004-4221.2015.06.003.
doi: 10.3760/cma.j.issn.1004-4221.2015.06.003 |
| [39] |
徐裕金, 朱卫国, Liao Z, 等. 同步放化疗60 Gy对比50 Gy剂量治疗不可手术食管鳞状细胞癌的多中心随机对照研究[J]. 中华医学杂志, 2020, 100(23): 1783-1788. DOI: 10.3760/cma.j.cn112137-20200303-00574.
doi: 10.3760/cma.j.cn112137-20200303-00574 |
| [40] |
Ji Y, Du X, Zhu W, et al. Efficacy of concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer: a multicenter randomized phase 3 clinical trial[J]. JAMA Oncol, 2021, 7(10): 1459-1466. DOI: 10.1001/jamaoncol.2021.2705.
doi: 10.1001/jamaoncol.2021.2705 pmid: 34351356 |
| [41] |
Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl): S42-S49. DOI: 10.1016/j.ijrobp.2009.04.095.
doi: 10.1016/j.ijrobp.2009.04.095 |
| [42] |
Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl): S10-S19. DOI: 10.1016/j.ijrobp.2009.07.1754.
doi: 10.1016/j.ijrobp.2009.07.1754 |
| [43] |
Mizumoto M, Sugahara S, Nakayama H, et al. Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer[J]. Strahlenther Onko, 2010, 186(9): 482-488. DOI: 10.1007/s00066-010-2079-4.
doi: 10.1007/s00066-010-2079-4 |
| [44] |
Xi M, Xu C, Liao Z, et al. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer: a retrospective, single-institutional analysis[J]. Int J Radiat Oncol Biol Phys, 2017, 99(3): 667-676. DOI: 10.1016/j.ijrobp.2017.06.2450.
doi: 10.1016/j.ijrobp.2017.06.2450 |
| [45] |
Fernandes A, Berman AT, Mick R, et al. A prospective study of proton beam reirradiation for esophageal cancer[J]. Int J Radiat Oncol Biol Phys, 2016, 95(1): 483-487. DOI: 10.1016/j.ijrobp.2015.12.005.
doi: 10.1016/j.ijrobp.2015.12.005 |
| [46] |
Routman DM, Garant A, Lester SC, et al. A comparison of grade 4 lymphopenia with proton versus photon radiation therapy for esophageal cancer[J]. Adv Radiat Oncol, 2019, 4(1): 63-69. DOI: 10.1016/j.adro.2018.09.004.
doi: 10.1016/j.adro.2018.09.004 pmid: 30706012 |
| [47] |
Akutsu Y, Yasuda S, Nagata M, et al. A phase Ⅰ/Ⅱ clinical trial of preoperative short-course carbon-ion radiotherapy for patients with squamous cell carcinoma of the esophagus[J]. J Surg Oncol, 2012, 105(8): 750-755. DOI: 10.1002/jso.22127.
doi: 10.1002/jso.22127 |
| [48] |
Li P, Fan J, Zhang K, et al. Interstitial 125Ⅰ brachytherapy as a salvage treatment for refractory cervical lymph node metastasis of thoracic esophageal squamous cell carcinoma after external irradiation with a CT-guided coplanar template-assisted technique: a retrospective study[J]. Technol Cancer Res Treat, 2022, 21: 15330338221103102. DOI: 10.1177/15330338221103102.
doi: 10.1177/15330338221103102 |
| [49] |
Zhu HD, Guo JH, Mao AW, et al. Conventional stents versus stents loaded with 125iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(6): 612-619. DOI: 10.1016/S1470-2045(14)70131-7.
doi: 10.1016/S1470-2045(14)70131-7 |
| [50] |
Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group[J]. JAMA, 1999, 281(17): 1623-1627. DOI: 10.1001/jama.281.17.1623.
doi: 10.1001/jama.281.17.1623 |
| [51] |
Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study[J]. Lancet Oncol, 2018, 19(7): 965-974. DOI: 10.1016/S1470-2045(18)30201-8.
doi: 10.1016/S1470-2045(18)30201-8 |
| [52] |
Noordman BJ, Wijnhoven BPL, Lagarde SM, et al. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial[J]. BMC Cancer, 2018, 18(1): 142. DOI: 10.1186/s12885-018-4034-1.
doi: 10.1186/s12885-018-4034-1 pmid: 29409469 |
| [53] |
Wainberg ZA, Lin LS, DiCarlo B, et al. Phase Ⅱ trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction[J]. Br J Cancer, 2011, 105(6): 760-765. DOI: 10.1038/bjc.2011.280.
doi: 10.1038/bjc.2011.280 |
| [54] |
Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma[J]. J Clin Oncol, 2018, 36(1): 61-67. DOI: 10.1200/JCO.2017.74.9846.
doi: 10.1200/JCO.2017.74.9846 pmid: 29116900 |
| [55] |
Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer[J]. N Engl J Med, 2021, 384(13): 1191-1203. DOI: 10.1056/NEJMoa2032125.
doi: 10.1056/NEJMoa2032125 |
| [56] |
Huang J, Xu B, Mo H, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma[J]. Clin Cancer Res, 2018, 24(6): 1296-1304. DOI: 10.1158/1078-0432.CCR-17-2439.
doi: 10.1158/1078-0432.CCR-17-2439 pmid: 29358502 |
| [57] |
Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer[J]. J Clin Oncol, 2018, 36(28): 2836-2844. DOI: 10.1200/JCO.2017.76.6212.
doi: 10.1200/JCO.2017.76.6212 pmid: 30110194 |
| [58] |
Alsina M, Moehler M, Lorenzen S. Immunotherapy of esophageal cancer: current status, many trials and innovative strategies[J]. Oncol Res Treat, 2018, 41(5): 266-271. DOI: 10.1159/000488120.
doi: 10.1159/000488120 pmid: 29705786 |
| [59] |
Meindl-Beinker NM, Betge J, Gutting T, et al. A multicenter open-label phase Ⅱ trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)[J]. BMC Cancer, 2019, 19(1): 231. DOI: 10.1186/s12885-019-5446-2.
doi: 10.1186/s12885-019-5446-2 pmid: 30871493 |
| [60] |
Ralph C, Elkord E, Burt DJ, et al. Modulation of lymphocyte regulation for cancer therapy: a phase Ⅱ trial of tremelimumab in advanced gastric and esophageal adenocarcinoma[J]. Clin Cancer Res, 2010, 16(5): 1662-1672. DOI: 10.1158/1078-0432.CCR-09-2870.
doi: 10.1158/1078-0432.CCR-09-2870 |
| [61] | Merck. FDA approves new monotherapy indication for Merck's KEYTRUDA® (pembrolizumab)[EB/OL]. [2019-07-31]. https://www.merck.com/news/fda-approves-new-monotherapy-indication-for-mercks-keytruda-pembrolizumab/. |
| [62] |
Wang H, Mu X, He H, et al. Cancer radiosensitizers[J]. Trends Pharmacol Sci, 2018, 39(1): 24-48. DOI: 10.1016/j.tips.2017.11.003.
doi: S0165-6147(17)30220-1 pmid: 29224916 |
| [63] |
康梅, 权循凤. 食管癌放疗增敏剂的临床研究[J]. 国际肿瘤学杂志, 2015, 42(12): 932-935. DOI: 10.3760/cma.j.issn.1673-422X.2015.12.013.
doi: 10.3760/cma.j.issn.1673-422X.2015.12.013 |
| [64] |
邓家营, 王春雨, 赵快乐. 紫杉醇(PTX)在食管癌同期放化疗中的研究进展[J]. 复旦学报(医学版), 2014, 41(5): 697-700. DOI: 10.3969/j.issn.1672-8467.2014.05.023.
doi: 10.3969/j.issn.1672-8467.2014.05.023 |
| [65] |
Ruhstaller T, Pless M, Dietrich D, et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resec-table, locally advanced esophageal carcinoma: a prospective, multicenter phase ⅠB/Ⅱ trial (SAKK 75/06)[J]. J Clin Oncol, 2011, 29(6): 626-631. DOI: 10.1200/JCO.2010.31.9715.
doi: 10.1200/JCO.2010.31.9715 pmid: 21205757 |
| [66] |
Li W, Chen P, Zhang N, et al. Endostatin and oxaliplatin-based chemoradiotherapy for inoperable esophageal squamous cell carcinoma: results of a phase Ⅱ study[J]. Oncologist, 2019, 24(4): 461-e136. DOI: 10.1634/theoncologist.2019-0119.
doi: 10.1634/theoncologist.2019-0119 |
| [67] |
Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(11): 1224-1235. DOI: 10.1016/S1470-2045(14)70420-6.
doi: 10.1016/S1470-2045(14)70420-6 |
| [68] |
秦尚彬, 王雅棣, 杨俊泉, 等. 甘氨双唑钠胸段食管鳞癌放射增敏作用——Ⅲ期多中心随机对照研究[J]. 中华放射肿瘤学杂志, 2012, 21(5): 426-429. DOI: 10.3760/cma.j.issn.1004-4221.2012.05.009.
doi: 10.3760/cma.j.issn.1004-4221.2012.05.009 |
| [69] |
Steward WP, Middleton M, Benghiat A, et al. The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase Ⅰ study[J]. Ann Oncol, 2007, 18(6): 1098-1103. DOI: 10.1093/annonc/mdm120.
doi: 10.1093/annonc/mdm120 pmid: 17442658 |
| [70] |
龚林吉, 谢佳妮, 朱双, 等. 多功能纳米材料在肿瘤放疗增敏中的应用[J]. 物理化学学报, 2018, 34(2): 140-167. DOI: 10.3866/PKU.WHXB201707174.
doi: 10.3866/PKU.WHXB201707174 |
| [71] |
吕家华, 李涛. 食管癌放疗患者的营养治疗[J]. 肿瘤代谢与营养电子杂志, 2017, 4(2): 144-148. DOI: 10.16689/j.cnki.cn11-9349/r.2017.02.003.
doi: 10.16689/j.cnki.cn11-9349/r.2017.02.003 |
| [72] |
Lyu J, Li T, Xie C, et al. Enteral nutrition in esophageal cancer patients treated with radiotherapy: a Chinese expert consensus 2018[J]. Future Oncol, 2019, 15(5): 517-531. DOI: 10.2217/fon-2018-0697.
doi: 10.2217/fon-2018-0697 pmid: 30457348 |
| [73] |
Xu YJ, Cheng JC, Lee JM, et al. A walk-and-eat intervention improves outcomes for patients with esophageal cancer undergoing neoadjuvant chemoradiotherapy[J]. Oncologist, 2015, 20(10): 1216-1222. DOI: 10.1634/theoncologist.2015-0178.
doi: 10.1634/theoncologist.2015-0178 |
| [74] |
Lyu J, Shi A, Li T, et al. Effects of enteral nutrition on patients with oesophageal carcinoma treated with concurrent chemoradiotherapy: a prospective, multicentre, randomised, controlled study[J]. Front Oncol, 2022, 12: 839516. DOI: 10.3389/fonc.2022.839516.
doi: 10.3389/fonc.2022.839516 |
| [75] |
Fietkau R, Lewitzki V, Kuhnt T, et al. A disease-specific enteral nutrition formula improves nutritional status and functional performance in patients with head and neck and esophageal cancer undergoing chemoradiotherapy: results of a randomized, controlled, multicenter trial[J]. Cancer, 2013, 119(18): 3343-3353. DOI: 10.1002/cncr.28197.
doi: 10.1002/cncr.28197 pmid: 23765693 |
| [76] | Businesswire. Checkmate-649 C, a phase 3 trial evaluating opdivo (nivolumab) plus chemotherapy vs. Chemotherapy, meets primary endpoints demonstrating superior overall survival and progression-free survival in first-line treatment of gastric and esophageal cancers[EB/OL]. [2020-08-11]. https://www.businesswire.com/news/home/20200811005245/en/. |
| [77] | Merck. Merck's KEYTRUDA® (pembrolizumab) in combination with chemotherapy significantly improved overall survival and progression-free survival compared with chemotherapy in locally advanced or first-line metastatic esophageal cancer[EB/OL]. [2020-08-19]. https://www.merck.com/news/mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-significantly-improved-overall-survival-and-progression-free-survival-compared-with-chemotherapy-in-locally-advanced-or/. |
| [78] | Businesswire. Opdivo (nivolumab) demonstrated superior disease-free survival in patients with resected esophageal or gastroesophageal junction cancer compared to placebo in the adjuvant setting[EB/OL]. [2020-09-21]. https://www.businesswire.com/news/home/20200921005657/en/. |
| [79] |
Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018, 36(27): 2796-2803. DOI: 10.1200/JCO.2018.79.1483.
doi: 10.1200/JCO.2018.79.1483 |
| [80] |
Qian D, Wang Y, Zhao G, et al. Tumor remission and tumor-infiltrating lymphocytes during chemoradiation therapy: predictive and prognostic markers in locally advanced esophageal squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2019, 105(2): 319-328. DOI: 10.1016/j.ijrobp.2019.06.079.
doi: 10.1016/j.ijrobp.2019.06.079 |
| [81] |
Jayaprakasam VS, Yeh R, Ku GY, et al. Role of imaging in esophageal cancer management in 2020: update for radiologists[J]. AJR Am J Roentgenol, 2020, 215(5): 1072-1084. DOI: 10.2214/AJR.20.22791.
doi: 10.2214/AJR.20.22791 |
| [82] |
Ono T. Review of clinical results of charged-particle therapy for esophageal cancer[J]. Esophagus, 2021, 18(1): 33-40. DOI: 10.1007/s10388-020-00759-0.
doi: 10.1007/s10388-020-00759-0 |
| [83] |
Zhang J, Li M, Zhang K, et al. Concurrent chemoradiation of different doses (50.4 Gy vs. 59.4 Gy) and different target field (ENI vs. IFI) for locally advanced esophageal squamous cell carcinoma: results from a randomized, multicenter phase Ⅲ clinical trial[J]. Int J Radiat Oncol Biol Phys, 2022, 114(3 Supplement): S15. DOI: 10.1016/j.ijrobp.2022.07.357.
doi: 10.1016/j.ijrobp.2022.07.357 |
| [84] |
Liu Y, Zheng Z, Li M, et al. Comparison of concurrent chemoradiotherapy with radiotherapy alone for locally advanced esophageal squamous cell cancer in elderly patients: a randomized, multicenter, phase Ⅱ clinical trial[J]. Int J Cancer, 2022, 151(4): 607-615. DOI: 10.1002/ijc.34030.
doi: 10.1002/ijc.34030 |
| [85] |
Sun H, Yang W, Luo J, et al. Safety and tolerability of neoadjuvant radiotherapy combined with anti-PD-1 antibody toripalimab for locally advanced, resectable esophageal squamous cell cancer: a prospective phase ⅠB trial[J]. Int J Radiat Oncol Biol Phys, 2021, 111(3 Supplement): S102-S103. DOI: 10.1016/j.ijrobp.2021.07.238.
doi: 10.1016/j.ijrobp.2021.07.238 |
| [86] |
Zhang W, Yan C, Zhang T, et al. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study[J]. Oncoimmunology, 2021, 10(1): 1971418. DOI: 10.1080/2162402X.2021.1971418.
doi: 10.1080/2162402X.2021.1971418 |
| [87] |
He W, Leng X, Mao T, et al. Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma[J]. Oncologist, 2022, 27(1): e18-e28. DOI: 10.1093/oncolo/oyab011.
doi: 10.1093/oncolo/oyab011 pmid: 35305102 |
| [88] |
Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40. DOI: 10.1016/S0140-6736(21)00797-2.
doi: 10.1016/S0140-6736(21)00797-2 pmid: 34102137 |
| [89] | Chau I, Dok Y, Ajani JA, et al. Nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: first results of the CheckMate 648 study[C]. ASCO, 2021: LBA4001. |
| [90] |
Boku N, Ryu MH, Kato K, et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase Ⅱ trial (ATTRACTION-4)[J]. Ann Oncol, 2019, 30(2): 250-258. DOI: 10.1093/annonc/mdy540.
doi: S0923-7534(19)31036-1 pmid: 31987422 |
| [91] |
Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302): 759-771. DOI: 10.1016/S0140-6736(21)01234-4.
doi: 10.1016/S0140-6736(21)01234-4 |
| [92] |
Kojima T, Shah MA, Muro K, et al. Randomized phase Ⅲ KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer[J]. J Clin Oncol, 2020, 38(35): 4138-4148. DOI: 10.1200/JCO.20.01888.
doi: 10.1200/JCO.20.01888 |
| [93] |
Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial[J]. JAMA, 2021, 326(10): 916-925. DOI: 10.1001/jama.2021.12836.
doi: 10.1001/jama.2021.12836 pmid: 34519801 |
| [94] |
Peng Z, Liu T, Wei J, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase Ⅱ study[J]. Cancer Commun (Lond), 2021, 41(11): 1173-1182. DOI: 10.1002/cac2.12214.
doi: 10.1002/cac2.12214 |
| [95] |
Qian D, Chen X, Shang X, et al. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: a phase Ⅱ random[J]. Radiother Oncol, 2022, 174: 1-7. DOI: 10.1016/j.radonc.2022.06.015.
doi: 10.1016/j.radonc.2022.06.015 |
| [96] |
Koyanagi K, Kato K, Ito Y, et al. Impact of preoperative therapy for locally advanced thoracic esophageal cancer on the risk of perioperative complications: results from multicenter phase Ⅲ trial JCOG 1109[J]. J Clin Oncol, 2021, 39(3_suppl): 162. DOI: 10.1200/JCO.2021.39.3_suppl.162.
doi: 10.1200/JCO.2021.39.3_suppl.162 |
| [97] |
Lu Z, Wang J, Shu Y, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial[J]. BMJ, 2022, 377: e068714. DOI: 10.1136/bmj-2021-068714.
doi: 10.1136/bmj-2021-068714 |
| [98] |
Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial[J]. Cancer Cell, 2022, 40(3): 277-288.e3. DOI: 10.1016/j.ccell.2022.02.007.
doi: 10.1016/j.ccell.2022.02.007 |
| [99] |
Shen L, Kato K, Kim SB, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase Ⅲ study[J]. J Clin Oncol, 2022, 40(26): 3065-3076. DOI: 10.1200/JCO.21.01926.
doi: 10.1200/JCO.21.01926 |
| [100] |
Zhang Q, Kong L, Liu R, et al. Ion therapy guideline (Version 2020)[J]. Precis Radiat Oncol, 2021, 5(2): 73-83. DOI: 10.1002/pro6.1120.
doi: 10.1002/pro6.1120 |
| [101] | Huang J, Song Y, Kou XG, et al. First-line serplulimab versus placebo in combination with chemotherapy in PD-L1-positive esophageal squamous cell carcinoma (ASTRUM-007): a rando-mized, double-blind, multicenter phase 3 study[C]. 2022年CSCO学术年会论文汇编, 北京: 临床肿瘤学杂志, 2022. |
| [1] | 杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337. |
| [2] | 高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381. |
| [3] | 刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273. |
| [4] | 万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209. |
| [5] | 李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174. |
| [6] | 李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125. |
| [7] | 中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20. |
| [8] | 高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42. |
| [9] | 崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552. |
| [10] | 山东省医学会肺癌食管癌多学科联合委员会. 山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397. |
| [11] | 李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367. |
| [12] | 许萌, 姜伟, 朱海涛, 曹雄锋. 癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230. |
| [13] | 石小琪, 汪红艳. 肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247. |
| [14] | 冀世玉, 张明鑫, 谢华红, 白渊, 王彤. 不同支架治疗晚期食管癌患者的疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 76-81. |
| [15] | 巩合义, 伊艳, 张健, 李宝生. 局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略[J]. 国际肿瘤学杂志, 2023, 50(12): 745-750. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
